8 results found.

Pompe Disease Clinical Trial using Alglucosidase alfa

Sanofi - Recruiting N/A or older.
- A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune Complex Mediated Reactions With Alglucosidase Alfa Treatment.
Alglucosidase alfa

Pompe Disease Clinical Trial using Albuterol; Placebo

Duke University - Recruiting 18 years or older.
- A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy.
Albuterol; Placebo

Pompe Disease, Glycogen Storage Disease Type II (GSD-II), or Acid Clinical Trial using alglucosidase alfa

Sanofi - Recruiting N/A to 24 Months.
- A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Myozyme (Alglucosidase Alfa)..
alglucosidase alfa

Pompe Disease Clinical Trial

University of Florida - Recruiting N/A to 65 years.
- Effects of Immunomodulation Therapy on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy.

Pompe Disease Clinical Trial using Clenbuterol; Placebo

Duke University - Recruiting 18 years or older.
- A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy.
Clenbuterol; Placebo

Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD Clinical Trial using alglucosidase alfa

Genzyme, a Sanofi Company - Recruiting 8 years to 18 years.
- A Phase IV Prospective Study to Characterize the Pharmacokinetics of Alglucosidase in Patients Aged 8-18 Years of Age.
alglucosidase alfa

Pompe Disease, Glycogen Storage Disease Type II (GSD-II), or Glyc Clinical Trial using Myozyme (alglucosidase alfa)

Genzyme, a Sanofi Company - Recruiting 1 Month or older.
- An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients With Pompe Disease Who Have Previously Received Myozyme.
Myozyme (alglucosidase alfa)

Glycogen Storage Disease Type II, or Pompe Disease Clinical Trial

Genzyme, a Sanofi Company - Recruiting N/A or older.
- Pompe Disease Registry.